Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Hanjing Chen"'
Autor:
Chao Liu, Hongrong Xu, Fei Yuan, Hanjing Chen, Lei Sheng, Weili Chen, Haisong Xie, Hongmei Xu, Xuening Li
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog, and its pharmacokinetic and pharmacodynamic properties as a GLP-1 receptor (GLP-1R) agonist make it an important therapeutic option for many patients with type 2 diabetes
Externí odkaz:
https://doaj.org/article/88f05422118f440692036318970a88a0
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity studies were conducted to evaluate the bioequivalence of CMAB807, a biosimilar to denosumab (Prolia®), which is the only approved RANKL inhibitor for the treatment of
Externí odkaz:
https://doaj.org/article/a3ce38e4720a48a08ddfb85b5bc8707a
Autor:
Fei, Yuan, Jing, Li, Xuening, Li, Hui, Li, Weili, Chen, Mengjie, Yang, Hanjing, Chen, Lei, Sheng, Chao, Liu, Yujia, Wu, Hongrong, Xu
Publikováno v:
Clinical Pharmacology in Drug Development. 12:168-174
Chiglitazar, a pan agonist of non-thiazolidinedione peroxisome proliferator-activated receptor, has the potential to regulate blood sugar, improve lipid metabolism, and reduce cardiovascular complications. This study aimed to examine the effect of cy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af033e3b1166f970682e7eb386028e14
https://doi.org/10.1002/cpdd.1198
https://doi.org/10.1002/cpdd.1198
Autor:
Chao Liu, Hongrong Xu, Fei Yuan, Hanjing Chen, Lei Sheng, Weili Chen, Haisong Xie, Hongmei Xu, Xuening Li
Publikováno v:
Frontiers in Pharmacology; 2024, p01-10, 10p
Publikováno v:
Biochemical and Biophysical Research Communications. 606:55-60
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator of LDLR, has emerged as an important target for the treatment of hypercholesterolemic cardiovascular disease, and monoclonal antibodies alirocumab and evolocumab against it h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d580922c5b72e19e7d1276e11485e7a1
https://doi.org/10.1016/j.bbrc.2022.03.066
https://doi.org/10.1016/j.bbrc.2022.03.066
Autor:
Hanjing Chen
Publikováno v:
Proceedings of the 2nd International Conference on Culture, Design and Social Development (CDSD 2022) ISBN: 9782384760176
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::722880d006ae225c48069c26331e6417
https://doi.org/10.2991/978-2-38476-018-3_16
https://doi.org/10.2991/978-2-38476-018-3_16
Publikováno v:
Leadership & Organization Development Journal. 42:1153-1167
PurposeThe purpose of this paper is to investigate the double-edged effects of supervisor bottom-line mentality (BLM) on subordinates' work-related behaviors (work performance and knowledge hiding) and the moderating role of subordinate gender.Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9441a77bac81d954fc204a0e90e255e9
https://doi.org/10.1108/lodj-11-2020-0491
https://doi.org/10.1108/lodj-11-2020-0491
Autor:
Lei Sheng, Mengjie Yang, Chunjiu Zhong, Wei-Li Chen, Chao Liu, Xue-Ning Li, Ping-ping Lin, Wei Cao, Hanjing Chen, Fei Yuan, Hui Li, Hong-Rong Xu
Publikováno v:
Drug Design, Development and Therapy
Lei Sheng,1,* Wei Cao,2,* Pingping Lin,3 Weili Chen,1 Hongrong Xu,1 Chunjiu Zhong,4 Fei Yuan,1 Hanjing Chen,1 Hui Li,1 Chao Liu,1 Mengjie Yang,1 Xuening Li1 1Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462c90484b2cf584b18a1b7f72d4ddb9
https://doi.org/10.2147/dddt.s296197
https://doi.org/10.2147/dddt.s296197
Autor:
Fei Yuan, Hui Li, Mengjie Yang, Weili Chen, Hanjing Chen, Hongrong Xu, Jing Li, Lei Sheng, Chao Liu, Ye Li, Huan Li, Xuening Li
Publikováno v:
Clinical pharmacology in drug developmentReferences.
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester that has been approved to lower triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Before this study, there were n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae0e205ae5bcf1369811fc2e6723020
https://pubmed.ncbi.nlm.nih.gov/35781804
https://pubmed.ncbi.nlm.nih.gov/35781804
Autor:
Wei-Li Chen, S. Aubrey Stoch, Hanjing Chen, Yang Liu, Chao Liu, Lei Sheng, Hui Li, Mengjie Yang, Rajesh Krishna, Fei Yuan, Xue-Ning Li, Ferdous Gheyas, Marian Iwamoto, Ping-ping Lin, Hong-Rong Xu, Brittany Walker
Publikováno v:
Advances in therapy. 38(7)
Anacetrapib is a novel, powerful cholesteryl ester transfer protein (CETP) inhibitor with bidirectional lipid regulation, which was developed for dyslipidemia. The aim of this study is to evaluate the single- and multiple-dose pharmacokinetics (PK),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8996b4baca42528998c39b3e44e354e
https://pubmed.ncbi.nlm.nih.gov/34101144
https://pubmed.ncbi.nlm.nih.gov/34101144